PAHC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PA

Mkt Cap

$1.58B

Volume

134.98K

Next Earnings

November 4th

Loading chart

PA

PAHCPhibro Animal Health Corporation Class A

PAHC

Pay with—

Available Balance0.00

PA

Mkt Cap

$1.58B

Volume

134.98K

Next Earnings

November 4th

Chart Financials Earnings News About Dividends Insider Filings

Reasons to Add STE Stock to Your Portfolio Right NowSTERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth.Zacks Investment Research · Oct 16, 2026

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures.Zacks Investment Research · Oct 16, 2026

Is it Apt to Retain Medtronic Stock in Your Portfolio Now?Medtronic is expanding its presence in high-growth markets including cardiac ablation (up 88%), robotics, and structural heart, while advancing the MiniMed separation. The company is building its hypertension business through the Symplicity Spyral renal denervation franchise with improved reimbursement and clinical evidence. However, Medtronic faces headwinds from tariffs, inflation, currency fluctuations, and unfavorable product mix that could pressure margins.Zacks Investment Research · Oct 16, 2026

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises. However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average.Zacks Investment Research · Oct 15, 2026

Is it the Right Time to Hold TNDM Stock in Your Portfolio?Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026.Zacks Investment Research · Oct 9, 2026

Is it the Right Time to Add Phibro Stock to Your Portfolio?Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.Zacks Investment Research · Oct 8, 2026

Encompass Health Expands Rehab Footprint With New Maine HospitalEncompass Health Corporation (EHC) opened its first wholly owned hospital in Maine with 50 inpatient rehabilitation beds. Q2 2026 discharges rose 5.6% year-over-year, driven by new capacity and 2.8% same-store growth. EHC opened three hospitals in the first half of 2026 and plans to open eight new hospitals throughout the year, reflecting its strategy to expand capacity in favorable markets.Zacks Investment Research · Oct 7, 2026

Is This the Right Time to Add TMO Stock to Your Portfolio?Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins.Zacks Investment Research · Oct 7, 2026

Neogen Stock Rallies 83% YTD: What's Driving the Surge?Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.Zacks Investment Research · Oct 1, 2026

Should You Continue to Hold IART Stock in Your Portfolio?Integra LifeSciences (IART) reported 1.6% organic growth in Specialty Surgery revenues driven by neurosurgery strength and improved supply reliability. Adjusted EPS rose 24.4% with margin expansion, and the company is ramping up Braintree production for a SurgiMend relaunch. However, elevated leverage at 4.1X and foreign exchange headwinds pressured full-year revenue guidance and financial flexibility.Zacks Investment Research · Sep 30, 2026

to start trading

PA

PAHCPhibro Animal Health Corporation Class A

PAHC

Pay with—

Available Balance0.00

Your PositionYou don't own any PAHC yet.

Related Tickers

Earnings

Dividends

Last · Sep 2Quarterly

Amount$0.12

Yield1.24%

Annual$0.48